Yuanyuan Cheng1, Lishuang Lin2, Xiaoyan Li3, Aiqi Lu2, Chenjian Hou4, Qian Wu2, Xiaomu Hu2, Zhongwen Zhou2, Zhongqing Chen2, Feng Tang2. 1. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. chengwang0915@163.com. 2. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China. 3. Department of Surgery, Huashan Hospital, Fudan University, Shanghai, China. 4. Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat, because it is so aggressive with shorter survival. Chemotherapy remains the standard treatment due to the lack of specific and effective molecular targets. The aim of the present study is to investigate the potential roles of A Disintegrin and Metalloproteinase 10 (ADAM10) on TNBC cells and the effects of combining ADAM10 expression and neoadjuvant chemotherapy treatment (NACT) to improve the overall survival in breast cancer patients. METHODS: Using a series of breast cancer cell lines, we measured the expression of ADAM10 and its substrates by quantitative real-time PCR assay (qRT-PCR) and western blot analysis. Cell migration and invasion, cell proliferation, drug sensitivity assay, cell cycle and apoptosis were conducted in MDA-MB-231 cells cultured with ADAM10 siRNA. The effect of ADAM10 down-regulation by siRNA on its substrates was assessed by western blot analysis. We performed immunohistochemical staining for ADAM10 in clinical breast cancer tissues in 94 patients receiving NACT. RESULTS: The active form of ADAM10 was highly expressed in TNBC cell lines. Knockdown of ADAM10 in MDA-MB-231 cells led to a significant decrease in cell proliferation, migration, invasion and the IC50 value of paclitaxel and adriamycin, while induced cell cycle arrest and apoptosis. And these changes were correlated with down-regulation of Notch signaling, CD44 and cellular prion protein (PrPc). In clinical breast cancer cases, a high ADAM10 expression in pre-NACT samples was strongly associated with poorer response to NACT and shorter overall survival. CONCLUSIONS: These data suggest the previously unrecognized roles of ADAM10 in contributing to the progression and chemo-resistance of TNBC.
BACKGROUND: Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat, because it is so aggressive with shorter survival. Chemotherapy remains the standard treatment due to the lack of specific and effective molecular targets. The aim of the present study is to investigate the potential roles of A Disintegrin and Metalloproteinase 10 (ADAM10) on TNBC cells and the effects of combining ADAM10 expression and neoadjuvant chemotherapy treatment (NACT) to improve the overall survival in breast cancerpatients. METHODS: Using a series of breast cancer cell lines, we measured the expression of ADAM10 and its substrates by quantitative real-time PCR assay (qRT-PCR) and western blot analysis. Cell migration and invasion, cell proliferation, drug sensitivity assay, cell cycle and apoptosis were conducted in MDA-MB-231 cells cultured with ADAM10 siRNA. The effect of ADAM10 down-regulation by siRNA on its substrates was assessed by western blot analysis. We performed immunohistochemical staining for ADAM10 in clinical breast cancer tissues in 94 patients receiving NACT. RESULTS: The active form of ADAM10 was highly expressed in TNBC cell lines. Knockdown of ADAM10 in MDA-MB-231 cells led to a significant decrease in cell proliferation, migration, invasion and the IC50 value of paclitaxel and adriamycin, while induced cell cycle arrest and apoptosis. And these changes were correlated with down-regulation of Notch signaling, CD44 and cellular prion protein (PrPc). In clinical breast cancer cases, a high ADAM10 expression in pre-NACT samples was strongly associated with poorer response to NACT and shorter overall survival. CONCLUSIONS: These data suggest the previously unrecognized roles of ADAM10 in contributing to the progression and chemo-resistance of TNBC.
Entities:
Keywords:
A disintegrin and metalloproteinase 10 (ADAM10); CD44; Cellular prion protein (PrPc); Notch1 signaling; Triple-negative breast cancer (TNBC)
Authors: Michael O Idowu; Maciej Kmieciak; Catherine Dumur; Regina S Burton; Margaret M Grimes; Celeste N Powers; Masoud H Manjili Journal: Hum Pathol Date: 2011-08-10 Impact factor: 3.466
Authors: Monika Hartmann; Liseth M Parra; Anne Ruschel; Christina Lindner; Helen Morrison; Andreas Herrlich; Peter Herrlich Journal: J Biol Chem Date: 2015-04-29 Impact factor: 5.157
Authors: Michael Reedijk; Silvia Odorcic; Lynn Chang; Hui Zhang; Naomi Miller; David R McCready; Gina Lockwood; Sean E Egan Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701
Authors: Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys Journal: Breast Date: 2003-10 Impact factor: 4.380
Authors: Dieter Hartmann; Bart de Strooper; Lutgarde Serneels; Katleen Craessaerts; An Herreman; Wim Annaert; Lieve Umans; Torben Lübke; Anna Lena Illert; Kurt von Figura; Paul Saftig Journal: Hum Mol Genet Date: 2002-10-01 Impact factor: 6.150
Authors: Ichiro Inoshima; Naoko Inoshima; Georgia A Wilke; Michael E Powers; Karen M Frank; Yang Wang; Juliane Bubeck Wardenburg Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Maeve Mullooly; Patricia M McGowan; Susan A Kennedy; Stephen F Madden; John Crown; Norma O' Donovan; Michael J Duffy Journal: Br J Cancer Date: 2015-08-18 Impact factor: 7.640